GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » EV-to-EBITDA

Vaxart (STU:NB11) EV-to-EBITDA : -1.52 (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Vaxart EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vaxart's enterprise value is €101.84 Mil. Vaxart's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-66.96 Mil. Therefore, Vaxart's EV-to-EBITDA for today is -1.52.

The historical rank and industry rank for Vaxart's EV-to-EBITDA or its related term are showing as below:

STU:NB11' s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.54   Med: -1.03   Max: 0.95
Current: -1.51

During the past 13 years, the highest EV-to-EBITDA of Vaxart was 0.95. The lowest was -67.54. And the median was -1.03.

STU:NB11's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.55 vs STU:NB11: -1.51

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Vaxart's stock price is €0.6375. Vaxart's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.538. Therefore, Vaxart's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Vaxart EV-to-EBITDA Historical Data

The historical data trend for Vaxart's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart EV-to-EBITDA Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.47 -18.61 -9.80 -0.55 -0.95

Vaxart Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.52 -0.69 -1.04 -0.95

Competitive Comparison of Vaxart's EV-to-EBITDA

For the Biotechnology subindustry, Vaxart's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vaxart's EV-to-EBITDA falls into.



Vaxart EV-to-EBITDA Calculation

Vaxart's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=101.842/-66.957
=-1.52

Vaxart's current Enterprise Value is €101.84 Mil.
Vaxart's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-66.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxart  (STU:NB11) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vaxart's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.6375/-0.538
=At Loss

Vaxart's share price for today is €0.6375.
Vaxart's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.538.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Vaxart EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vaxart's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (STU:NB11) Business Description

Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines